Cytokinetics Shares Fall On Drug Development Delay

NEW YORK (AP) ¿ Shares of Cytokinetics Inc. plunged Thursday after the biotechnology company said development of a potential heart failure drug could take a year longer than previously anticipated.

The stock slid 76 cents, or 17.8 percent, to $3.51 in afternoon trading. Shares have traded between $1.38 and $5.55 over the last 52 weeks.

Late Wednesday, the company said it agreed with partner Amgen Inc. on conducting additional mid-to-late-stage studies on omecamtiv mecarbil for heart failure and renal dysfunction patients in 2011.

Lazard Capital Markets analyst Joel Sendek reaffirmed a "Buy" rating on Cytokinetics, but said the delayed timeline could affect milestone payments to Cytokinetics.

Cytokinetics also said its third-quarter loss narrowed on more revenue from collaborations.

The company recorded a loss of $8.2 million, or 14 cents per share, compared with a loss of $16.3 million, or 33 cents per share, during the same period a year prior. Revenue rose 76 percent to $5.5 million from $3.1 million.

Analysts polled by Thomson Reuters expected a loss of 22 cents per share on revenue of $2.9 million.

Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

More from Investing

A Thunderous Herd of Scared Baby Boomer Investors Could Crush the Market

A Thunderous Herd of Scared Baby Boomer Investors Could Crush the Market

With GE Dropped From the Dow, Be Selective About Industrials Stocks

With GE Dropped From the Dow, Be Selective About Industrials Stocks

GE Headed to $9.99 a Share?

GE Headed to $9.99 a Share?

3 Ways to Fix Starbucks Biggest Challenges

3 Ways to Fix Starbucks Biggest Challenges

Oracle's Soft Guidance and Move to Not Break Out Cloud Revenues Are Worrying

Oracle's Soft Guidance and Move to Not Break Out Cloud Revenues Are Worrying